Ultomiris Approved in Scotland for Patients Weighing at Least 10 kg

Ultomiris Approved in Scotland for Patients Weighing at Least 10 kg

294084

Ultomiris Approved in Scotland for Patients Weighing at Least 10 kg

Ultomiris (ravulizumab) has been approved in Scotland for adults and children weighing at least 10 kg, or 22 lbs, with atypical hemolytic uremic syndrome (aHUS). Ultomiris is Alexion Pharmaceuticals’ successor to Soliris (eculizumab), also approved for aHUS. Both therapies work by blocking the activity of the complement C5 protein, preventing the overactivation of the complement system and destruction of red blood cells, which characterize aHUS. The complement system is a set of more than 30…

You must be logged in to read/download the full post.